Chardan Healthcare Acquisition 2 Corp. Completes Business Combination with Renovacor, Inc.

Rocket Pharmaceuticals Acquires Renovacor

September 20, 2022

Biotechnology

Rocket Pharmaceuticals (NASDAQ: RCKT) will acquire Renovacor (NYSE: RCOR) in an all-stock transaction valued at approximately $53 million (implied $2.60 per Renovacor share). The acquisition strengthens Rocket's leadership in AAV-based cardiac gene therapy by adding Renovacor's REN-001 BAG3-targeted program and related capabilities to Rocket's clinical pipeline.

Viveon Health Acquisition Corp. to Merge with Suneva Medical

January 12, 2022

Medical Devices

Suneva Medical, a San Diego–based regenerative aesthetics medical technology company, has entered into a definitive merger agreement with special purpose acquisition company Viveon Health Acquisition Corp. The transaction will combine Suneva with the public SPAC vehicle (NYSE American: VHAQ) to provide growth capital and public-market access for Suneva, with the combined company expected to trade on the NYSE under the symbol "RNEW."

ChrysCapital Acquires Minority Stake in La Renon

April 16, 2024

Pharmaceuticals

India-focused PE firm ChrysCapital is investing about $70 million to acquire a minority stake in Ahmedabad-based pharmaceutical company La Renon. The growth investment will support La Renon's expansion plans across chronic therapeutic segments, strengthen manufacturing and R&D capabilities, and fund geographic expansion into international markets.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Novo Nordisk Acquires Cardior Pharmaceuticals from EQT Life Sciences

March 25, 2024

Biotechnology

Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to EUR 1.025 billion, including an upfront payment and contingent development and commercial milestone payments. Cardior, a Hannover-based clinical-stage biotech focused on RNA-targeted therapies for cardiovascular disease, is currently majority-backed by EQT Life Sciences; the deal is expected to close in Q2 2024 subject to regulatory approvals.

Renovus Capital Partners Acquires QualX Corporation

September 11, 2024

Government & Public Sector

Renovus Capital Partners has acquired QualX Corporation, a Springfield, Virginia-based provider of records and information management, digital transformation, and business process improvement services to U.S. federal agencies. Renovus will support QualX in investing in technology, expanding the team, pursuing strategic acquisitions, and extending the company's federal footprint. Financial terms were not disclosed.